Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- PUR1900 Phase 2b study progressing with 17 active sites, topline data expected in H2 2024
- Received 'study may proceed' letter for Phase 2 study of PUR3100 for acute migraine
- Cash and cash equivalents of $21.3 million providing projected cash runway into Q1 2025
- Revenues decreased by $0.1 million to $1.8 million for Q3 2023
Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in H2 2024
Received "study may proceed" letter on an IND for a Phase 2 study of PUR3100 for acute migraine
Ted Raad, Chief Executive Officer of Pulmatrix commented, "Our PUR1900 Phase 2b study in allergic bronchopulmonary aspergillosis, or ABPA, is ongoing with newly activated sites now contributing to enrollment efforts. With receipt of the FDA "study may proceed" letter for PUR3100 announced in September 2023, we anticipate initiating the PUR3100 Phase 2 study once appropriate financing or partnership has been arranged. While we continue to advance our clinical programs, we believe we have maintained operational efficiency to preserve our projected cash runway into the first quarter of 2025."
Third Quarter 2023 and Recent Program and Corporate Highlights
PUR1900
- Since February 2023, PUR1900 (itraconazole, administered as a dry powder for inhalation using iSPERSE™) has been in a Phase 2 trial for the treatment of ABPA in patients with asthma (NCT05667662). This trial is a randomized, double-blind, multi-center, placebo-controlled study to evaluate PUR1900's efficacy and safety. The multi-center study is being conducted in
the United States ,United Kingdom ,Australia andFrance . Endpoints include safety, tolerability, and potential efficacy outcomes to identify potential registrational endpoints in adult patients with asthma and ABPA. Pulmatrix currently anticipates topline data from this study in the second half of 2024. - The current Phase 2 trial of PUR1900 builds on the results of the Phase 1 trial, which were published earlier this year in the peer-reviewed American Association of Pharmaceutical Scientists (AAPS) Journal and titled "Evaluation of the Potential for Drug‑Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data". Results demonstrated a low likelihood of clinically meaningful drug-drug interactions with inhaled PUR1900 as opposed to the known contraindications that exist with various medications when combined with oral itraconazole, demonstrating the potential advantage of inhaled therapeutics.
PUR3100
- In September 2023, Pulmatrix announced FDA acceptance of its Phase 2 IND application for PUR3100 and receipt of a "study may proceed" letter for a Phase 2 study. The IND includes a Phase 2 clinical protocol where safety and preliminary efficacy of PUR3100, an orally inhaled dihydroergotamine (DHE) engineered with iSPERSE™, will be evaluated in patients with acute migraine. Pulmatrix is currently pursuing potential partnership opportunities to further develop this product candidate.
- The current planned Phase 2 trial builds on the Phase 1 trial results, which were published earlier this year and presented at the American Headache Society 65th Annual Meeting in June 2023. Compared to patients dosed with intravenously (IV) administered DHE, subjects dosed with PUR3100 showed a lower incidence of nausea, and no vomiting was observed in PUR3100 dose groups compared to the intravenously (IV) administered DHE dose group. The study also showed that PUR3100 achieved peak exposures in the targeted therapeutic range and time to maximum concentration occurred at five minutes after dosing at all dosing levels.
PUR1800
- Earlier this year, Pulmatrix presented complete results from a Phase 1b study of PUR1800 for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The Company expects that the completed data analysis will inform the study design of a potential Phase 2 study in patients with AECOPD. Pulmatrix plans to pursue partnership opportunities to advance PUR1800 into a potential Phase 2 clinical trial.
Third Quarter 2023 Financial Results
Revenues decreased
Research and development expenses decreased approximately
General and administrative expenses remained at
Pulmatrix's total cash and cash equivalents balance as of September 30, 2023 was
PULMATRIX, INC. | ||||||||
Consolidated Balance Sheets | ||||||||
(in thousands, except share and per share data) | ||||||||
September 30, 2023 | December 31, 2022 | |||||||
(unaudited) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 21,336 | $ | 35,628 | ||||
Restricted cash | 153 | 153 | ||||||
Accounts receivable | 841 | 1,298 | ||||||
Prepaid expenses and other current assets | 899 | 1,068 | ||||||
Total current assets | 23,229 | 38,147 | ||||||
Property and equipment, net | 1,166 | 235 | ||||||
Operating lease right-of-use asset | 10,686 | 710 | ||||||
Long-term restricted cash | 1,472 | 1,472 | ||||||
Other long-term assets | 217 | 389 | ||||||
Total assets | $ | 36,770 | $ | 40,953 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 707 | $ | 1,188 | ||||
Accrued expenses and other current liabilities | 2,535 | 1,638 | ||||||
Operating lease liability | 199 | 857 | ||||||
Deferred revenue | 988 | 1,339 | ||||||
Total current liabilities | 4,429 | 5,022 | ||||||
Deferred revenue, net of current portion | 4,038 | 4,822 | ||||||
Operating lease liability, net of current portion | 8,422 | - | ||||||
Total liabilities | 16,889 | 9,844 | ||||||
Stockholders' equity: | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | - | - | ||||||
Additional paid-in capital | 305,395 | 304,585 | ||||||
Accumulated deficit | (285,514) | (273,476) | ||||||
Total stockholders' equity | 19,881 | 31,109 | ||||||
Total liabilities and stockholders' equity | $ | 36,770 | $ | 40,953 | ||||
PULMATRIX, INC. | ||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||
(in thousands, except share and per share data) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Revenues | $ | 1,753 | $ | 1,872 | $ | 5,096 | $ | 4,363 | ||||||||
Operating expenses | ||||||||||||||||
Research and development | 3,963 | 5,287 | 12,002 | 13,773 | ||||||||||||
General and administrative | 1,729 | 1,685 | 5,609 | 5,212 | ||||||||||||
Total operating expenses | 5,692 | 6,972 | 17,611 | 18,985 | ||||||||||||
Loss from operations | (3,939) | (5,100) | (12,515) | (14,622) | ||||||||||||
Other income (expense) | ||||||||||||||||
Interest income | 217 | 102 | 675 | 118 | ||||||||||||
Other expense, net | (52) | (54) | (198) | (116) | ||||||||||||
Total other income (expense), net | 165 | 48 | 477 | 2 | ||||||||||||
Net loss | $ | (3,774) | $ | (5,052) | $ | (12,038) | $ | (14,620) | ||||||||
Net loss per share attributable to common stockholders – basic and diluted | $ | (1.03) | $ | (1.45) | $ | (3.30) | $ | (4.32) | ||||||||
Weighted average common shares outstanding – basic and diluted | 3,652,285 | 3,478,157 | 3,651,785 | 3,383,171 | ||||||||||||
About Pulmatrix, Inc.
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases and central nervous system ("CNS") disorders using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for lung diseases, such as allergic bronchopulmonary aspergillosis ("ABPA"), Chronic Obstructive Pulmonary Disease ("COPD") and CNS disorders such as acute migraine. Pulmatrix's product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
For more on our inhaled product candidates please visit: https://www.pulmatrix.com/pipeline.html.
Forward-Looking Statements
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the impact of the novel coronavirus (COVID-19) endemic on the Company's ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on the Company's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Timothy McCarthy, CFA
917-679-9282
tim@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pulmatrix-announces-third-quarter-2023-financial-results-and-provides-corporate-update-301982988.html
SOURCE Pulmatrix Inc.
FAQ
What is Pulmatrix, Inc.'s cash and cash equivalents at the end of Q3 2023?
What is the status of the PUR1900 Phase 2b study?
What is the latest development regarding PUR3100?
What are the recent financial results of Pulmatrix, Inc.?
